TY - JOUR
T1 - Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy
AU - Sarayba, Melvin A.
AU - Shamie, Neda
AU - Reiser, B. J.
AU - Sweet, Paula M.
AU - Taban, Mehran
AU - Graff, Jordan M.
AU - Kesler-Diaz, Anna
AU - Osann, Kathryn E.
AU - McDonnell, Peter J.
N1 - Funding Information:
Supported by an unrestricted gift to support research from Allergan Pharmaceuticals Inc, Irvine, California, USA.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005/7
Y1 - 2005/7
N2 - Purpose: To characterize a rabbit model of Mycobacterium chelonae keratitis after lamellar keratectomy and assess the effectiveness of fluoroquinolone therapy. Setting: University Laboratory, University of California, Irvine, California, USA. Methods: Twenty-eight New Zealand white rabbits had unilateral lamellar keratectomy with placement of 2.5 × 105 colony-forming units of log-phase M chelonae under each flap. Eyes (7 per group) were randomized and treated with sterile balanced salt solution, gatifloxacin 0.3%, ciprofloxacin 0.3%, or levofloxacin 0.5% 4 times daily. Two masked observers examined all eyes on days 2, 5, and 7 and weekly for 4 weeks. Severity of disease and bacterial culture results were the main outcomes measured. The means and standard deviations were calculated, and differences between the groups were statistically analyzed. Results: All eyes developed clinical disease. At the time the rabbits were killed, eyes treated with balanced salt solution, ciprofloxacin, levofloxacin, and gatifloxacin were culture positive in 6 (85.7%), 7 (100%), 6 (85.7%), and 3 (42.9%) of 7 eyes per group, respectively. Frequency of positive culture and the severity of clinical disease in gatifloxacin-treated eyes were significantly less (P < .05) than in the other groups combined. Conclusions: The rabbit model of M chelonae keratitis was successfully developed in our study. A fourth-generation quinolone (gatifloxacin) showed the best performance among the fluoroquinolones tested in our experimental approach. The fourth-generation fluoroquinolone, gatifloxacin, could be effectively used for the treatment of mycobacterial keratitis.
AB - Purpose: To characterize a rabbit model of Mycobacterium chelonae keratitis after lamellar keratectomy and assess the effectiveness of fluoroquinolone therapy. Setting: University Laboratory, University of California, Irvine, California, USA. Methods: Twenty-eight New Zealand white rabbits had unilateral lamellar keratectomy with placement of 2.5 × 105 colony-forming units of log-phase M chelonae under each flap. Eyes (7 per group) were randomized and treated with sterile balanced salt solution, gatifloxacin 0.3%, ciprofloxacin 0.3%, or levofloxacin 0.5% 4 times daily. Two masked observers examined all eyes on days 2, 5, and 7 and weekly for 4 weeks. Severity of disease and bacterial culture results were the main outcomes measured. The means and standard deviations were calculated, and differences between the groups were statistically analyzed. Results: All eyes developed clinical disease. At the time the rabbits were killed, eyes treated with balanced salt solution, ciprofloxacin, levofloxacin, and gatifloxacin were culture positive in 6 (85.7%), 7 (100%), 6 (85.7%), and 3 (42.9%) of 7 eyes per group, respectively. Frequency of positive culture and the severity of clinical disease in gatifloxacin-treated eyes were significantly less (P < .05) than in the other groups combined. Conclusions: The rabbit model of M chelonae keratitis was successfully developed in our study. A fourth-generation quinolone (gatifloxacin) showed the best performance among the fluoroquinolones tested in our experimental approach. The fourth-generation fluoroquinolone, gatifloxacin, could be effectively used for the treatment of mycobacterial keratitis.
UR - http://www.scopus.com/inward/record.url?scp=24944461867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944461867&partnerID=8YFLogxK
U2 - 10.1016/j.jcrs.2004.12.051
DO - 10.1016/j.jcrs.2004.12.051
M3 - Article
C2 - 16105613
AN - SCOPUS:24944461867
SN - 0886-3350
VL - 31
SP - 1396
EP - 1402
JO - Journal of cataract and refractive surgery
JF - Journal of cataract and refractive surgery
IS - 7
ER -